Nektar Therapeutics (NKTR) has drawn investor attention after its stock closed at $76.03, with sizeable moves over the past month and past 3 months prompting a closer look at the biopharmaceutical company.

Over the past year, Nektar Therapeutics has seen strong momentum, with a year-to-date share price return of 75.1% and a 1-year total shareholder return of 195.61%. However, the 5-year total shareholder return remains significantly negative, which highlights how recent gains sit against a tougher longer-term record and may point to shifting views on its growth prospects and risk profile.

If Nektar Therapeutics has you rethinking where the next big move could come from, it may be worth scanning a curated list of 43 healthcare AI stocks as a way to spot other potential opportunities in related areas.

Nektar Therapeutics now trades at a sizeable discount to the average analyst price target, even after this sharp run. Is the market being too cautious on the pipeline risk, or are analysts leaning too far ahead of events?

Most Popular Narrative: 50.4% Undervalued

On the most followed narrative, Nektar Therapeutics screens as heavily undervalued, with a fair value of $153.25 against the recent $76.03 close, which puts its story-driven assumptions in sharp focus.

Strong initial Phase IIb and ongoing data for REZPEG in atopic dermatitis, combined with a large and growing addressable market (expected to reach nearly $30B by 2033), position Nektar to access significant new revenue streams and improve long-term earnings as the population ages and chronic inflammatory diseases rise globally.

Want to see what sits behind that optimism for Nektar Therapeutics? The narrative leans on aggressive revenue expansion, margin improvement and a rich future earnings multiple. Curious which assumptions really carry the $153.25 figure?

Based on this narrative, the discount rate used is 7.108%, with revenue expected to contract slightly overall yet still support a very large future P/E multiple on projected earnings by 2029. The same framework assumes Nektar Therapeutics eventually reaches profit margins in line with the wider US pharmaceuticals group, despite analysts currently expecting the company to remain loss making for at least the next three years.

That gap between today’s loss making status and the earnings power implied by the narrative also feeds into the analyst price target range, from $80 at the low end through to $192 at the top end. The wide spread underlines how sensitive Nektar Therapeutics’ estimated fair value is to clinical outcomes, eventual pricing and how much of the potential addressable market the company is assumed to capture.

Result: Fair Value of $153.25 (UNDERVALUED)

However, Nektar Therapeutics still faces key risks, including its continued losses and heavy dependence on REZPEG outcomes, which could quickly challenge this undervaluation story.

Another View on Nektar Therapeutics: What P/S Says

The earlier fair value of $153.25 for Nektar Therapeutics leans heavily on long term earnings potential from the pipeline. A simpler cross check using the current P/S of 46.2x paints a different picture. The stock trades far above the US pharmaceuticals group at 5x and the peer average at 12.3x, and even above a fair ratio of 16.3x that the market could eventually move toward. That gap suggests investors are already paying a high price for future success, so the key question is how much execution risk you are comfortable carrying at today’s level.

Next Steps

If this mix of optimism and caution around Nektar Therapeutics feels familiar, do not wait to weigh it up against your own risk tolerance and time horizon. Then see how that balance of concerns and potential upsides stacks up in our 1 key reward and 3 important warning signs

Looking for more investment ideas beyond Nektar Therapeutics?

If you are weighing Nektar Therapeutics and do not want to miss other potential setups, use the Simply Wall St screener to hunt for fresh opportunities that fit your style.

• Spot underappreciated opportunities early by scanning screener containing 20 high quality undiscovered gems that pair solid fundamentals with quieter market attention.
• Build a watchlist of potential compounding stories by reviewing 49 high quality undervalued stocks where quality and pricing look out of sync.
• Focus on stability first by assessing 85 resilient stocks with low risk scores that score well on resilience and balance sheet strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.